You are here

P&T News

March 29

First medication for both relapsing and primary progressive forms of the disease
President remains optimistic after House debacle
Panel wants to know whether pharma companies contributed to opioid epidemic
Health care CEOs look for solutions

March 28

PARP inhibitor improves progression-free survival
Prevention, screening, treatment, and creative financing for medication sought
Threat highest in Southeast, southern Atlantic Coast, and southern California
New Leapfrog methodology and grades due soon

March 27

Developers to file NDA in second half of 2017
Controversies are critiqued and data-derived recommendations are proposed
Devices may not power up, charge, or deliver shock therapy
Scientists find previously unknown genetic changes that predispose patients to glioma
New patent battle focuses on Sovaldi, which costs thousands of dollars for a course

March 24

The human anti-PD-L1 antibody is the first therapy for this rare skin cancer
CTSA program paves way for nationwide single IRB model
MRIs more dependable than patient preference to determine best approach
John Hopkins experts call for early-detection strategies
Scientists working to develop the potential of nuclear receptors

Pages